Cumberland Partners’s Edwards Lifesciences EW Stock Holding History

Cumberland Partners’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,000	Closed	-$853K	–	169
2025 Q4	$853K	Buy	+10,000	New	+$821K	0.05%	141

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Cumberland Partners's EW Position: Q1 2026 in Review

Cumberland Partners sold out of Edwards Lifesciences (EW) in Q1 2026, closing a stake of 10,000 shares — an estimated $853K sold.

Cumberland Partners first reported a position in EW in Q4 2025 and held it in 1 quarter. The position peaked at $853K in Q4 2025. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

Cumberland Partners reported no remaining Edwards Lifesciences position as of Q1 2026 after selling out during the quarter.
Cumberland Partners sold 10,000 Edwards Lifesciences shares in Q1 2026, an estimated $853K.
Cumberland Partners first reported a position in Edwards Lifesciences in Q4 2025 and held it in 1 quarter.
Cumberland Partners's Edwards Lifesciences position peaked at $853K in Q4 2025.
1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Cumberland Partners's 13F filing for Q1 2026, filed 14 May 2026.